Low-dose naltrexone as a treatment for chronic fatigue syndrome.
Bolton, Monica Jane, Chapman, Bryan Paul, Van Marwijk, Harm · BMJ case reports · 2020 · DOI
Quick Summary
This study describes three people with ME/CFS who tried taking low-dose naltrexone (LDN), a medication sometimes used off-label for immune-related conditions. The patients experienced different results—some reported major improvements in their quality of life, while others noticed only modest reductions in specific symptoms like pain or fatigue. The doses used were quite small (4-12 mg), and the authors suggest that larger clinical trials might be worth doing to properly test whether LDN could help ME/CFS patients.
Why It Matters
ME/CFS currently has no FDA-approved or widely accepted pharmacological treatments, making exploration of any potentially beneficial option clinically important. This case series bridges the gap between internet-reported anecdotal success with LDN and rigorous clinical evidence, providing preliminary justification for funding controlled trials. Understanding which ME/CFS patients might respond to repurposed medications like naltrexone could offer hope to severely disabled patients seeking symptom management strategies.
Response range included life-changing improvements in some patients and reduction of specific symptoms (pain, fatigue) in others
No serious adverse events were documented in these case reports
Patients self-reported improvements in fatigue, pain, autonomic symptoms, and functional capacity
Treatment duration and specific symptom profiles varied across the three cases
Inferred Conclusions
Low-dose naltrexone may have potential therapeutic utility in ME/CFS based on preliminary patient reports
LDN's suspected mechanism in other immune-modulated conditions warrants investigation in ME/CFS cohorts
Clinical trials are needed to systematically evaluate LDN efficacy, optimal dosing, and safety in ME/CFS populations
Remaining Questions
Would LDN show efficacy in a randomized, placebo-controlled trial in ME/CFS patients?
What is the optimal dose range and duration of treatment for ME/CFS, and are there predictive biomarkers of responders?
What This Study Does Not Prove
This study cannot establish efficacy, causation, or safe dosing—it is three anecdotal reports without a control group, blinding, or objective outcome measures. The observed improvements may reflect placebo effect, natural variation in ME/CFS symptoms, concurrent lifestyle changes, or regression to the mean rather than naltrexone's pharmacological action. Extrapolating from three positive/partial responses to a general ME/CFS population would be premature without randomized controlled trial evidence.